Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Vapreotide
Overview
Vapreotide is a synthetic octapeptide analog of somatostatin with enhanced selectivity for somatostatin receptor subtypes 2 and 5. It exerts antisecretory and antiproliferative effects by binding to these receptors on neuroendocrine tumor cells and inhibiting hormone release.
Mechanism of Action
The therapeutic rationale centers on control of symptoms associated with vasoactive intestinal peptide secreting tumors and other neuroendocrine malignancies. Its longer half-life compared to native somatostatin allows for sustained receptor occupancy.
Research Summary & Key Findings
Clinical trials evaluated vapreotide for acute variceal bleeding and neuroendocrine tumor symptom control, though efficacy compared to octreotide was not consistently superior. The compound has been studied in phase III trials but did not achieve broad regulatory approval for oncology indications. Most clinical experience is derived from European studies in the 1990s and early 2000s.
Clinical Status
Vapreotide is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Vapreotide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Vapreotide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Vapreotide"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Oncology
Carfilzomib (Kyprolis)
FDA ApprovedA tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S...
View detailsBortezomib (Velcade)
FDA ApprovedA modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortez...
View detailsLutetium-177 dotatate (Lutathera)
FDA ApprovedA radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioiso...
View detailsLeuprolide (Lupron) - Oncology
FDA ApprovedA GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in pre...
View detailsNo lawful pathway today
Vapreotide is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.